
Rewriting the Oncology Playbook
Dr Mark Eccleston, Director of Inaphaea, discusses how patient-derived 3D models can bridge the translational divide in oncology. Drug development is a… Read More

Dr Mark Eccleston, Director of Inaphaea, discusses how patient-derived 3D models can bridge the translational divide in oncology. Drug development is a… Read More

3D spheroid models and live-cell analysis are powerful tools transforming drug discovery and cancer science. Download this eBook ‘Exploring the Versatility of Using 3D Spheroid Models in Research‘ from Sartorius to learn: How real-time imaging unlocks deeper insights Discover why 3D models outperform traditional cultures How to create more… Read More

3D spheroid models and live-cell analysis – powerful tools transforming drug discovery and cancer science! Download the eBook to learn: How real-time imaging unlocks deeper insights Discover why 3D models outperform traditional cultures How to create more reliable, clinically relevant cancer models Download now and accelerate your breakthroughs. … Read More

DDW’s Diana Turner speaks to Catherine Whittington, Associate Professor in the Department of Biomedical Engineering at WPI about her current work and the research that drives her. DT: Can you tell us what you do and what you’re working on at the moment? CW: I teach classes in the biomedical… Read More

Balancing assay throughput with physiological relevance is essential for improving disease modelling and compound screening in preclinical drug development. Induced pluripotent stem cell (iPSC) technology has revolutionised early drug discovery by integrating human biology, enhancing predictions of drug safety and efficacy. However, achieving both scalability and consistency in… Read More

Balancing assay throughput with physiological relevance is essential for improving disease modelling and compound screening in preclinical drug development. Induced pluripotent stem cell (iPSC) technology has revolutionised early drug discovery by integrating human biology, enhancing predictions of drug safety and efficacy. However, achieving both scalability and consistency in… Read More

Balancing assay throughput with physiological relevance is essential for improving disease modelling and compound screening in preclinical drug development. Induced pluripotent stem cell (iPSC) technology has revolutionised early drug discovery by integrating human biology, enhancing predictions of drug safety and efficacy. However, achieving both scalability and consistency in… Read More

Balancing assay throughput with physiological relevance is essential for improving disease modelling and compound screening in preclinical drug development. Induced pluripotent stem cell (iPSC) technology has revolutionised early drug discovery by integrating human biology, enhancing predictions of drug safety and efficacy. However, achieving both scalability and consistency in… Read More

Balancing assay throughput with physiological relevance is essential for improving disease modelling and compound screening in preclinical drug development. Induced pluripotent stem cell (iPSC) technology has revolutionised early drug discovery by integrating human biology, enhancing predictions of drug safety and efficacy. However, achieving both scalability and consistency in… Read More

News round-up for 7-11 April by DDW Senior Digital Content Editor Diana Spencer. As the political news brings more uncertainty for the sector, this week we are focusing on positive developments in the field of oncology, from the possibilities of cancer cures in the rainforest, to a new… Read More

Balancing assay throughput with physiological relevance is essential for improving disease modelling and compound screening in preclinical drug development. Induced pluripotent stem cell (iPSC) technology has revolutionised early drug discovery by integrating human biology, enhancing predictions of drug safety and efficacy. However, achieving both scalability and consistency in… Read More

Balancing assay throughput with physiological relevance is essential for improving disease modelling and compound screening in preclinical drug development. Induced pluripotent stem cell (iPSC) technology has revolutionised early drug discovery by integrating human biology, enhancing predictions of drug safety and efficacy. However, achieving both scalability and consistency in high-throughput applications… Read More

Join DDW and Lonza for this free event ‘Building advanced cell models for toxicity testing’. The event will take place on 19 September at 3pm GMT / 4pm CET / 10am EST / 7am PST. Life sciences researchers need a host… Read More

Join DDW and Lonza for this free event ‘Building advanced cell models for toxicity testing’. The event will take place on 19 September at 3pm GMT / 4pm CET / 10am EST / 7am PST. Life sciences researchers need a host… Read More

Join DDW and Lonza for this free event ‘Building advanced cell models for toxicity testing’. The event will take place on 19 September at 3pm GMT / 4pm CET / 10am EST / 7am PST. Life sciences researchers need a host… Read More

Join DDW and Lonza for this free event ‘Building advanced cell models for toxicity testing’. The event will take place on 19 September at 3pm GMT / 4pm CET / 10am EST / 7am PST. Life sciences researchers need a host… Read More